These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10611184)

  • 1. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation.
    Out HJ; Braat DD; Lintsen BM; Gurgan T; Bukulmez O; Gökmen O; Keles G; Caballero P; González JM; Fábregues F; Balasch J; Roulier R
    Hum Reprod; 2000 Jan; 15(1):29-35. PubMed ID: 10611184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation.
    Out HJ; Lindenberg S; Mikkelsen AL; Eldar-Geva T; Healy DL; Leader A; Rodriguez-Escudero FJ; Garcia-Velasco JA; Pellicer A
    Hum Reprod; 1999 Mar; 14(3):622-7. PubMed ID: 10221686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.
    Hoomans EH; Mulder BB;
    J Assist Reprod Genet; 2002 Oct; 19(10):470-6. PubMed ID: 12416651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.
    Wikland M; Bergh C; Borg K; Hillensjö T; Howles CM; Knutsson A; Nilsson L; Wood M
    Hum Reprod; 2001 Aug; 16(8):1676-81. PubMed ID: 11473962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.
    Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O
    Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
    Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H
    Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization.
    Latin-American Puregon IVF Study Group
    Fertil Steril; 2001 Nov; 76(5):950-6. PubMed ID: 11704116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles.
    Out HJ; David I; Ron-El R; Friedler S; Shalev E; Geslevich J; Dor J; Shulman A; Ben-Rafael Z; Fisch B; Dirnfeld M
    Hum Reprod; 2001 Jun; 16(6):1104-9. PubMed ID: 11387277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program].
    Tsagareishvili GG; Khonelidze NL; Lazarev AP
    Georgian Med News; 2005 Jun; (123):7-12. PubMed ID: 16052045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical efficacy and efficiency of a 100-IU starting dose of recombinant follicle stimulating hormone (Puregon) in Korean women undergoing in vitro fertilization and embryo transfer.
    Moon SY; Kim SH; Ku SY; Jee BC; Choi YM; Lee JY
    J Obstet Gynaecol Res; 2003 Jun; 29(3):174-9. PubMed ID: 12841702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study.
    Ng EY; Yeung WS; Ho PC
    Hong Kong Med J; 2000 Dec; 6(4):368-74. PubMed ID: 11177158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles.
    Strowitzki T; Kentenich H; Kiesel L; Neulen J; Bilger W
    Hum Reprod; 1995 Dec; 10(12):3097-101. PubMed ID: 8822421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction.
    Out HJ; Rutherford A; Fleming R; Tay CC; Trew G; Ledger W; Cahill D
    Hum Reprod; 2004 Jan; 19(1):90-5. PubMed ID: 14688163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.